Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT), a clinical-stage biotech focused on Bisphosphocin® antimicrobials, will present at the Life Sciences Virtual Investor Forum on June 25, 2026, at 11:30 AM EDT.

CEO Kelvin Cooper will discuss the company’s growth strategy and lead candidate Nu-3, a topical gel advancing into Phase 2 trials for infected diabetic foot ulcers.

News Market Reaction – LABT

-0.68% 1.7x vol

23 alerts

-0.68% Session close to close

-22.1% Trough in 4 hr 46 min

$9.74M Market Cap

1.7x Rel. Volume

In the Jun 16 session, LABT declined 0.68%, reflecting a mild negative market reaction. Argus tracked a trough of -22.1% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on an upcoming investor presentation outlining Lakewood-Amedex’s growth st...

Analysis

This announcement centers on an upcoming investor presentation outlining Lakewood-Amedex’s growth strategy and Nu-3 Phase 2 plans for infected diabetic foot ulcers. Recent filings show a net loss of $923,291, minimal quarter-end cash of $11,709, and reliance on a $7.5M Series C financing amid going-concern language. Investors may focus on clinical design, funding runway, and how management frames Nu-3’s path through Phase 2 and potential market positioning.

Key Figures

Presentation date: June 25, 2026 Presentation time: 11:30 AM EDT Trial phase: Phase 2

3 metrics

Presentation date June 25, 2026 Life Sciences Virtual Investor Forum

Presentation time 11:30 AM EDT Life Sciences Virtual Investor Forum

Trial phase Phase 2 Nu-3 clinical trials for infected diabetic foot ulcers

Historical Context

5 past events · Latest: May 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	IP expansion	Positive	+3.0%	Expanded Nu-3 IP with new patents in Australia and New Zealand.
May 18	Program progress	Positive	-36.6%	Positive Nu-3 data and manufacturing readiness for a Phase 2 trial.
May 12	CRO agreement	Positive	+1.9%	PERI engaged as CRO for Nu-3 Phase 2 clinical program.
May 01	AMR data	Positive	+28.9%	Favorable antimicrobial resistance profile for Nu-3 versus ciprofloxacin controls.
Apr 28	Board appointment	Positive	+6.3%	Appointment of experienced biotech CEO Joseph Tucker to the board.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive Nu-3 and corporate updates have often seen favorable or volatile price reactions, with one notable selloff despite upbeat data.

Recent Company History

In the last few months, Lakewood-Amedex focused on advancing lead candidate Nu-3 for infected diabetic foot ulcers and strengthening its corporate setup. On May 1, 2026, positive antimicrobial resistance data drove a 28.95% move. Subsequent agreements for a Phase 2 CRO on May 12 and expanded IP on May 27 supported the development pathway. However, positive advancement data on May 18 coincided with a -36.65% reaction, highlighting volatility around Nu-3 milestones.

Key Terms

clinical-stage, antimicrobials, infectious diseases, diabetic foot ulcers, +1 more

5 terms

clinical-stage medical

"a clinical-stage biotechnology company advancing a novel class of potent"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

antimicrobials medical

"a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases"

Antimicrobials are drugs and substances that kill or stop the growth of tiny organisms like bacteria, viruses, fungi and parasites — think of them as pesticides for germs. They matter to investors because demand, regulatory approval, resistance trends and public-health policies directly affect sales, research-and-development value and long-term market prospects for companies that make or sell these products.

infectious diseases medical

"broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin"

Infectious diseases are illnesses caused by germs—like bacteria, viruses, fungi or parasites—that can spread between people, animals or through contaminated surfaces. For investors they matter because outbreaks and ongoing transmission change demand for medical treatments, vaccines and diagnostics, alter healthcare costs and regulatory focus, and can disrupt supply chains and consumer behavior much like a sudden storm changes travel and commerce.

diabetic foot ulcers medical

"Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU)"

A diabetic foot ulcer is an open sore or wound on the foot that occurs when high blood sugar and nerve damage prevent normal healing, much like a small pothole that keeps widening because the road can’t be properly repaired. It matters to investors because these wounds drive demand for treatments, medical devices, wound-care drugs and hospital services, and they carry risks of infection and amputation that can shape healthcare costs, reimbursement decisions and clinical trial opportunities.

phase 2 clinical trials medical

"As we advance Nu-3 into Phase 2 clinical trials, we believe there is an opportunity"

Phase 2 clinical trials are mid-stage tests of a new treatment in a larger group of patients to assess whether it works and to further evaluate safety and dosing. Think of it like a more serious test drive after basic checks: success suggests the treatment has real potential and justifies larger, more expensive late-stage trials, which can increase a drug developer’s value to investors, while failure often leads to sharp declines in outlook.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026.

Presentation Details:

Event:	Life Sciences Virtual Investor Forum
Date/Time	June 25, 2026, at 11:30, AM EDT
Website	Registration Link

"We look forward to presenting Lakewood-Amedex Biotherapeutics' growth strategy and the ground-breaking potential of our lead candidate, Nu-3, a topical gel being developed for the treatment of infected diabetic foot ulcers (iDFU)," said Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development. "Mild iDFU impacts millions of people worldwide, potentially leading to serious infections and ultimately amputations. As we advance Nu-3 into Phase 2 clinical trials, we believe there is an opportunity to generate substantial value given the drug's unique mechanism of action and its potential to address a large and underserved patient population."

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum-302800916.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

When will Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) present at the Life Sciences Virtual Investor Forum?

Lakewood-Amedex Biotherapeutics will present on June 25, 2026, at 11:30 AM EDT. The company plans to outline its growth strategy and highlight its lead antimicrobial candidate Nu-3 for infected diabetic foot ulcers.

What is Lakewood-Amedex Biotherapeutics’ lead candidate Nu-3 and what condition is it targeting?

Nu-3 is a topical gel being developed to treat infected diabetic foot ulcers (iDFU). According to the company, Nu-3 has a unique mechanism of action and is advancing into Phase 2 clinical trials targeting a large, underserved patient population.

What will Lakewood-Amedex Biotherapeutics (LABT) discuss at the June 25, 2026 investor forum?

Lakewood-Amedex Biotherapeutics plans to present its growth strategy and the potential of Nu-3 at the forum. According to the company, the discussion will focus on its Bisphosphocin® antimicrobial platform and Nu-3’s Phase 2 development in infected diabetic foot ulcers.

How does Lakewood-Amedex Biotherapeutics describe the market need for Nu-3 in infected diabetic foot ulcers?

The company notes that mild iDFU affects millions worldwide and can lead to serious infections and amputations. According to Lakewood-Amedex, Nu-3 may address a large and underserved patient population and could create value if Phase 2 development progresses successfully.

What type of company is Lakewood-Amedex Biotherapeutics (LABT) and what technology is it developing?

Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company developing Bisphosphocin® antimicrobials. According to the company, these agents are designed as potent, fast-acting, broad-spectrum treatments for infectious diseases, with Nu-3 as its primary clinical candidate.